Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B, Beck LA, de Bruin-Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura MD, Chan G, Johnson S, Farooqui SA, Kerkmann U, Clibborn C. Reich K, et al. Among authors: biswas p. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2056-2066. doi: 10.1111/jdv.19280. Epub 2023 Jul 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37335885
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. Among authors: biswas p. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Ständer S, Valdez H, Rojo R, Biswas P, Myers DE, Feeney C, DiBonaventura M. Silverberg JI, et al. Among authors: biswas p. Am J Clin Dermatol. 2021 Jul;22(4):541-554. doi: 10.1007/s40257-021-00604-9. Epub 2021 May 5. Am J Clin Dermatol. 2021. PMID: 33954933 Free PMC article. Clinical Trial.
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Kim BS, Silverberg JI, Ständer S, Yosipovitch G, Simpson EL, DiBonaventura M, Kerkmann U, Farooqui SA, Biswas P, Valdez H, Cameron MC. Kim BS, et al. Among authors: biswas p. Dermatitis. 2021 Oct 1;32(1S):S39-S44. doi: 10.1097/DER.0000000000000770. Dermatitis. 2021. PMID: 34175862 Free PMC article.
Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI, Thyssen JP, Simpson EL, Yosipovitch G, Ständer S, Valdez H, Rojo R, Biswas P, Myers DE, Feeney C, DiBonaventura M. Silverberg JI, et al. Among authors: biswas p. Am J Clin Dermatol. 2021 Sep;22(5):739. doi: 10.1007/s40257-021-00634-3. Am J Clin Dermatol. 2021. PMID: 34406620 Free PMC article. No abstract available.
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE.
Gooderham MJ, Chu CY, Rojo R, Valdez H, Biswas P, Cameron MC, Feeney C, Encinas GA, Peeples-Lamirande K, Cappelleri JC, Myers DE, DiBonaventura M. Gooderham MJ, et al. Among authors: biswas p. JAAD Int. 2021 Jul 1;4:46-48. doi: 10.1016/j.jdin.2021.05.004. eCollection 2021 Sep. JAAD Int. 2021. PMID: 34409391 Free PMC article. No abstract available.
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Blauvelt A, et al. Among authors: biswas p. J Am Acad Dermatol. 2022 Jan;86(1):104-112. doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17. J Am Acad Dermatol. 2022. PMID: 34416294 Free article. Clinical Trial.
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H. Bieber T, et al. Among authors: biswas p. Immunotherapy. 2022 Jan;14(1):5-14. doi: 10.2217/imt-2021-0224. Epub 2021 Nov 15. Immunotherapy. 2022. PMID: 34775830 Free article.
High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
Ständer S, Bhatia N, Gooderham MJ, Silverberg JI, Thyssen JP, Biswas P, DiBonaventura M, Romero W, Farooqui SA. Ständer S, et al. Among authors: biswas p. J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1308-1317. doi: 10.1111/jdv.18170. Epub 2022 May 6. J Eur Acad Dermatol Venereol. 2022. PMID: 35462428 Free PMC article.
1,209 results